These findings indicate that Ang-II can regulate lymphangiogenesis in LECs via AT1R, highlighting the potential of AT1R blockers to treat hypertension and associated cardiovascular remodeling by targeting RIG-I. This evidence concerns the gene AGTR1 and hypertensive disorder.